These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 28371815

  • 21. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
    Zhang S, Guo J, Xie S, Chen J, Yu S, Yu Y.
    Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
    [Abstract] [Full Text] [Related]

  • 22. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis.
    Yang J, Xing J, Zhu X, Xie X, Wang L, Zhang X.
    Front Endocrinol (Lausanne); 2023 Jun; 14():1131516. PubMed ID: 37008953
    [Abstract] [Full Text] [Related]

  • 23. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM.
    Am J Nephrol; 2017 Jun; 45(5):380-388. PubMed ID: 28343225
    [Abstract] [Full Text] [Related]

  • 24. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T, Otsuka T, Reusch M, Ueno M.
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [Abstract] [Full Text] [Related]

  • 25. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH.
    Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q, Yang H, Sun L, Wei R, Fu X, Wang Y, Huang Y, Liu YN, Liu WJ.
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [Abstract] [Full Text] [Related]

  • 27. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.
    Tian L, Wang M, Liu M, Pang Y, Zhao J, Zheng B, Wang Y, Zhao W.
    Ren Fail; 2024 Dec; 46(1):2313864. PubMed ID: 38345037
    [Abstract] [Full Text] [Related]

  • 28. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T, Tsubakihara Y, Nangaku M, Endo Y, Nakajima H, Kohno T, Imai Y, Kawase N, Hara K, Lepore J, Cobitz A.
    Am J Nephrol; 2017 Dec; 45(2):127-135. PubMed ID: 27978511
    [Abstract] [Full Text] [Related]

  • 29. A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat.
    Locatelli F, Ravera M, Esposito C, Grandaliano G, Gesualdo L, Minutolo R.
    J Nephrol; 2024 May; 37(4):1107-1119. PubMed ID: 38189866
    [Abstract] [Full Text] [Related]

  • 30. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M.
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [Abstract] [Full Text] [Related]

  • 31. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [Abstract] [Full Text] [Related]

  • 32. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.
    Qie S, Jiao N, Duan K, Li J, Liu Y, Liu G.
    Int Urol Nephrol; 2021 May; 53(5):985-997. PubMed ID: 33389461
    [Abstract] [Full Text] [Related]

  • 33. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T, Ueno M, Shiga T, Reusch M.
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [Abstract] [Full Text] [Related]

  • 34. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
    Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Matsui A, Hirakata H.
    Am J Nephrol; 2019 Dec; 49(2):165-174. PubMed ID: 30699415
    [Abstract] [Full Text] [Related]

  • 35. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
    Kile M, Sudchada P.
    Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
    [Abstract] [Full Text] [Related]

  • 36. Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.
    Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD, Patel NB, Nakrani VB, Shaikh FA, Patel HV, on behalf of the ZYAN1 Trial Investigators.
    Am J Nephrol; 2019 Feb; 49(6):470-478. PubMed ID: 31112954
    [Abstract] [Full Text] [Related]

  • 37. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N, Wish JB.
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [Abstract] [Full Text] [Related]

  • 38. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T, Tanaka-Amino K, Otsuka T, Yamaguchi Y.
    Am J Nephrol; 2021 Jun; 52(9):702-713. PubMed ID: 34628408
    [Abstract] [Full Text] [Related]

  • 39. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS, Haase VH.
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
    [Abstract] [Full Text] [Related]

  • 40. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H, Cheng Q, Wang J, Zhao X, Zhu S.
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.